Future Forecasting

Week Two - August - 2-6

Week Two - August 2-6

How Diversity of Leadership can Incite Change for Patients from all Backgrounds.

On-Demand from August 2

This panel session will discuss the importance of intersectional diversity across all levels of leadership in the life sciences to ensure that underserved patients groups are fairly represented in all areas from drug development to employee healthcare.

Speakers:

Greg DeShields, Executive Director, PHL Diversity
Gbenga Olatunji, Director EMEA Pharma & Life sciences strategy, Strategy&
Gervan Williams, Director, Product Development and Innovation, LucasPye BIO
Cameron Bardliving, Director, PD & Operations, Jefferson Institute for Bioprocessing
Lisette Martinez, MBA, Executive Vice President and Chief Diversity Officer Jefferson Health and Thomas Jefferson University

Discussion Points:

Innovating to improve access to medicines.
The correlation of the effects of racism, poverty, and social instability of health and health outcomes.
Addressing academia’s responsibility to diversity in the pipeline
The employer's role in healthcare quality and health care costs and the future of healthcare plans post COVID-19.

Diversity, Equality and Inclusion

What role will Pharma play in the Healthcare System of 2022?

On-Demand from August 2

In this Fireside chat with Dr David Nash of Jefferson College of Population Health, we discuss the inequities of the current US healthcare system highlighted by the pandemic and the role pharma plays in the future of population health.

Speakers:

Dr David B. Nash, MD, MBA, Founding Dean Emeritus, Jefferson College of Population Health
Christopher P. Molineaux, President & CEO, Life Sciences PA

Discussion Points

How might Pharma get ahead of the price transparency curve by promoting public availability of prices?
What role can Pharma play in improving some of the SDOH that limit our ability to improve the health of the population?
How can we really harness patient-centred outcomes and Real World Evidence so that patient committees will actually pay attention?
In the healthcare system of the future, what expanded role might Pharma play to actually promote health?

Week Two - August 2-6

Diversity, Equality and Inclusion

The Women in Leadership Forum

Navigating the Road to Investment for Female Founders.

On-Demand from August 2

The Women in Leadership Forum is a place for women across the pharma supply chain to come together to connect, network and share ideas for successfully working and succeeding in the industry.

This year attendees will learn about various methods and routes to securing funding for female founders in pharma.

Speakers

Alise Cortez, Management Consultant / Chief Purpose Officer, Alise Cortez and Associates
Amy Peck, Founder & CEO, EndeavorVR
Sharon Cunningham, CEO, Shorla Pharma
Amita Goel, CEO, Celltheon
Tia Lyles-Williams, Founder & CEO, LucasPye BIO

Hear from successful female founders in the pharma and biotech space and meet like-minded women in a virtual networking session following the panel discussion.

Diversity, Equality and Inclusion

Week Two - August 2-6

De-risking Drug Development with Digital

On-Demand from August 3

Moving away from traditional costly time-consuming and often unsuccessful R&D methods, innovative companies are looking towards AI and machine learning to reduce costs and improve success rates in drug development. We explore the current projects that identify novel pathways, targets and biomarkers and discuss the challenges of biometric data security and how companies can work alongside existing regulations.

Speakers:

Maria Fátima Lucas, Co-Founder & CEO, Zymvol
Stefan Rottmann, External Data Protection Officer, Rottmanns IT Services
Stephanie Pasas Farmer, President & Founder, Ariadne Software

Discussion Points

A look at current regulations and how to make them work for you.
Federated learning in AI development
How biocatalysts are reshaping the synthesis of chemical entities.
The power of 3D molecular modelling

Drug Development

Week Two - August 2-6

The Lasting Impact of COVID-19 on Drug Development

LIVE SESSION: August 3, 2 pm EDT

A disrupter event to many business and industries worldwide, what lasting impacts will be felt and what can pharma learn from the COVID-19 pandemic in terms of the acceleration of drug development and repurposing in the future; the broader impact on how trials are conducted, and the impact of virtual clinical trials for clinical supplies business.

Speakers:

Anil Kane, Executive Director, Global Head of Technical & Scientific Affairs, Thermo Fisher Scientific.
Frances Zipp, President & CEO, Lachman Consultants
Mike Wenger, Vice President of Patient Engagement, Informa Pharma Intelligence

Discussion Points:

Fast-tracking R&D
Emergency use approvals
Drug Repurposing
Diversifying Clinical trials

Drug Development

Innovation in the Race to Vaccinate the World.

On-Demand from August 3

Vaccines are considered to be one of the greatest public health achievements of the last century, so when the COVID-19 pandemic brought the world to a stop, all energies were focused on bringing a vaccine to market. With multiple vaccines now approved and being manufactured in record time, we celebrate this accelerated pace of development in the field. Exploring the different vaccine technologies to understand their mode of action, benefits, risks, and potential real-life impact on protection. The challenges in manufacturing enough doses to vaccinate the world and the potential impact the WTO’s IP waiver proposal will have on future innovation.

Speakers

Fiona Barry, Associate Editor, GlobalData
Leonard Friedland, Vice President, Director Scientific Affairs and Public Health, GSK Vaccines
Dr Fintan Walton, CEO and Founder, PharmaVentures

Discussion Points:

Vaccine Science: Two Centuries of Continuous Research, Improvements, and Achievements
Future Potential of mRNA
Where are the facilities equipped for these new molecule types? What problems are arising and how is the industry working to fix them?
Vaccinating the world, a look at WTO’s proposed IP waiver and what it could mean for future innovation

Week Two - August 2-6

Drug Manufacturing

The Real Cost of Bringing Manufacturing Home

LIVE SESSION: August 4, 2 pm EDT

Many years before the pandemic the industry has highlighted the importance of a globalized supply chain and in particular the heavy reliance on Asian suppliers. The situation fueled calls from political leaders and lawmakers for U.S. manufacturers to start producing critical supplies domestically. But what will be the cost of bringing manufacturing home, and who will the burden lie on?

Speakers:

Wayne P. Weiner, Principal, Pharmatech Solutions
Bikash Chatterjee, Chief Executive Officer, Pharmatech Associates
Kenneth Drew, VP Flamma USA, FLAMMA
David R. Gaugh, R.Ph, Senior Vice President For Sciences And Regulatory Affairs, Association for Accessible Medicines (AAM)

Discussion Points:

What will the “Made in America” pledge deliver?
Can AI/Digitalization of facilities reduce costs?
Addressing the skills and facilities gap
Near-shoring – reducing dependence on Asian suppliers.

Drug Manufacturing

Building Supply Chain Resiliency & Continuity of Supply

On-Demand from August 4

When China went into lockdown in early 2020, manufacturing of critical ingredients, needed worldwide came to a standstill, and companies were forced to reevaluate their supply chains.

Forward to 2021, and companies across the globe are still dealing with port closures and shipments of expensive ingredients sat in a backlog, many are faced with the decision of either waiting weeks for deliveries or the faster, yet more expensive domestic production to ensure the continuity of supply of essential medicines.

Speakers:

David McCarthy, Senior Director, Sourcing Operations & Enablement, Pfizer, PSCI member
Thomas Udesen, Chief Procurement Officer, Bayer, Co-Founder of The Sustainable Procurement Pledge
Marcia Roeder, Senior Specialist, Strategic Philanthropy and Gifts In-Kind, International Medical Corps

Discussion Points:

Creating a geographically robust supply chain is critical for reducing drug shortages,
Ensuring essential medicines security through public-private partnerships
Risk management and the pivot to regional manufacturing hubs
Opportunities for manufacturing generic API’s

Week Two - August 2-6

Biologics & Biomanufacturing

Biosimilar Waves - Future of Biosimilar Approvals and Development.

On-Demand from August 5

Discussion Points:

Patent expiry opportunities 2021-2026
Catching up with Europe

Speaker:

Quentin Horgan, Analyst, Pharmaceuticals, GlobalData

Week Two - August 2-6